VivoSeq
Other

HNSCC

9

Pipeline Programs↗

14

Active Trials↗

8

Companies Involved↗

HNSCC is an early-stage landscape with 9 programs across 8 companies. The most active players are Bristol-Myers Squibb, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., BeiGene.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

27/100

Mech. Concentration

50/100

Completion Rate

50/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1S

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

1 program

Phase 2BeiGene logo

BeiGene

1 program

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

1 program

PreclinicalF

FBD Biologics Limited

1 program

PreclinicalMerck & Co. logo

Merck & Co.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody343%

Modality classified for 89% of 9 pipeline programs.

Analysis

Trial Status

27

clinical trials

Recruiting8 · 30%
Unknown status5 · 19%
Completed4 · 15%
Not yet recruiting4 · 15%
Terminated2 · 7%
Withdrawn2 · 7%
Other2 · 7%

Clinical Trials

Trial Activity

27 trials

Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Recruiting·UUniversity of California, Irvine·Phase 2·NCT06693323·34 enrolled
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06935188·98 enrolled
Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC
Recruiting·HHunan Cancer Hospital·Phase 2·NCT06752798·30 enrolled
De-escalation Radiation Strategy After NAC in Combination With ICI in LAHNSCC
Recruiting·RRuijin Hospital·Phase 1/2·NCT06572514·20 enrolled
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1·NCT06819228·60 enrolled
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
Recruiting·ZZhujiang Hospital·N/A·NCT07686575·20 enrolled
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Recruiting·VVanderbilt-Ingram Cancer Center·Phase 1·NCT07460765·40 enrolled
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
Recruiting·TTaipei Veterans General Hospital, Taiwan·Preclinical·NCT07136545·50 enrolled
Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
Active, not recruiting·—·Phase 1·NCT07435415·10 enrolled
A Prospective, Single-arm Clinical Study of Immune-targeted Therapy Combined With Lysogenic HSV Virus for the Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
Active, not recruiting·WWest China Hospital·Preclinical·NCT07010120·29 enrolled
AK117 (Anti-CD47) + Anti-EGFR for R/M HNSCC
Not yet recruiting·WWest China Hospital·Phase 2·NCT06508606·10 enrolled
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
Not yet recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 2·NCT06989671·430 enrolled
H101 Plus TACE for r/m HNSCC
Not yet recruiting·WWest China Hospital·Phase 2·NCT07398664·20 enrolled
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Not yet recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07668154·30 enrolled
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT01931150·11 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)